These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 1326689)

  • 41. Continuous intrathecal opioid treatment abolishes the regulatory effects of magnesium and guanine nucleotides on mu opioid receptor binding in rat spinal membranes.
    Wong CS; Su YF; Watkins WD; Chang KJ
    J Pharmacol Exp Ther; 1992 Jul; 262(1):317-26. PubMed ID: 1320689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vivo receptor binding of opioid drugs at the mu site.
    Rosenbaum JS; Holford NH; Sadée W
    J Pharmacol Exp Ther; 1985 Jun; 233(3):735-40. PubMed ID: 2989495
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor.
    Emmerson PJ; Clark MJ; Mansour A; Akil H; Woods JH; Medzihradsky F
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1121-7. PubMed ID: 8819494
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
    Traynor JR; Nahorski SR
    Mol Pharmacol; 1995 Apr; 47(4):848-54. PubMed ID: 7723747
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Purification of opioid-binding materials from rat brain.
    Fujioka T; Inoue F; Kuriyama M
    Biochem Biophys Res Commun; 1985 Sep; 131(2):640-6. PubMed ID: 2996518
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Functional reconstitution of a highly purified mu-opioid receptor protein with purified G proteins in liposomes.
    Fan LQ; Gioannini TL; Wolinsky T; Hiller JM; Simon EJ
    J Neurochem; 1995 Dec; 65(6):2537-42. PubMed ID: 7595548
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Novel diastereomeric opioid tetrapeptides exhibit differing pharmacological activity profiles.
    Ioja E; Tourwé D; Kertész I; Tóth G; Borsodi A; Benyhe S
    Brain Res Bull; 2007 Sep; 74(1-3):119-29. PubMed ID: 17683797
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Binding characteristics of [3H]opioid ligands to active opioid binding sites solubilized from rat brain membranes by glycodeoxycholate and NaCl: the recovery of binding activity by dilution.
    Maruyama M; Sugino H; Akita K; Hatanaka H
    Brain Res; 1987 Jan; 401(1):14-22. PubMed ID: 2880641
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Solubilization in high yield of opioid receptors retaining high-affinity delta, mu and kappa binding sites.
    Demoliou-Mason CD; Barnard EA
    FEBS Lett; 1984 May; 170(2):378-82. PubMed ID: 6144572
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Kinetics and physical parameters of rat brain opioid receptors solubilized by digitonin and CHAPS.
    Simon J; Benyhe S; Abutidze K; Borsodi A; Szücs M; Tóth G; Wollemann M
    J Neurochem; 1986 Mar; 46(3):695-701. PubMed ID: 3005492
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Opioid receptor interactions of butorphanol, a narcotic antagonist analgesic, and its metabolites].
    Nozaki M; Niwa M; Hasegawa J; Fujimura H
    Nihon Yakurigaku Zasshi; 1983 Dec; 82(6):443-50. PubMed ID: 6321306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Opioid receptor labeling with the chloromethyl ketone derivative of [3H]Tyr-D-Ala-Gly-(Me)Phe-Gly-ol (DAMGO) II: Covalent labeling of mu opioid binding site by 3H-Tyr-D-Ala-Gly-(Me)Phe chloromethyl ketone.
    Oktem HA; Moitra J; Benyhe S; Toth G; Lajtha A; Borsodi A
    Life Sci; 1991; 48(18):1763-8. PubMed ID: 1850495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Acute and chronic effects of opioids on delta and mu receptor activation of G proteins in NG108-15 and SK-N-SH cell membranes.
    Breivogel CS; Selley DE; Childers SR
    J Neurochem; 1997 Apr; 68(4):1462-72. PubMed ID: 9084416
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Some properties of brain opioid receptors in membrane bound and solubilized state.
    Ito Y; Makimura M; Murakoshi Y
    Neuropeptides; 1984 Dec; 5(1-3):193-6. PubMed ID: 6099495
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cross-linking of human [125I]beta-endorphin to opioid receptors in rat striatal membranes: biochemical evidence for the existence of a mu/delta opioid receptor complex.
    Schoffelmeer AN; Yao YH; Gioannini TL; Hiller JM; Ofri D; Roques BP; Simon EJ
    J Pharmacol Exp Ther; 1990 Apr; 253(1):419-26. PubMed ID: 2158552
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling.
    Yabaluri N; Medzihradsky F
    Mol Pharmacol; 1997 Nov; 52(5):896-902. PubMed ID: 9351981
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Naloxone activation of mu-opioid receptors mutated at a histidine residue lining the opioid binding cavity.
    Spivak CE; Beglan CL; Seidleck BK; Hirshbein LD; Blaschak CJ; Uhl GR; Surratt CK
    Mol Pharmacol; 1997 Dec; 52(6):983-92. PubMed ID: 9415708
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relationship of mu opioid receptor binding to activation of G-proteins in specific rat brain regions.
    Maher CE; Selley DE; Childers SR
    Biochem Pharmacol; 2000 Jun; 59(11):1395-401. PubMed ID: 10751548
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of mu-, delta- and kappa-opioid receptors in baculovirus-infected insect cells.
    Obermeier H; Wehmeyer A; Schulz R
    Eur J Pharmacol; 1996 Dec; 318(1):161-6. PubMed ID: 9007528
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decrease in mu-opioid receptor binding capacity in rat brain after chronic PL017 treatment.
    Tao PL; Lee HY; Chang LR; Loh HH
    Brain Res; 1990 Sep; 526(2):270-5. PubMed ID: 2175241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.